SEC Filing Summary: PerkinElmer, Inc. (10-Q)
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the three-month period ended March 30, 2008. PerkinElmer, Inc. operates in two primary segments: Life and Analytical Sciences (providing analysis tools, genetic screening, and laboratory services) and Optoelectronics (providing medical imaging, optical sensors, and specialty lighting). The company is a large accelerated filer incorporated in Massachusetts.
Key Financial Metrics
| Metric | Q1 2008 | Q1 2007 |
|---|---|---|
| Sales | $482.3 million | $402.9 million |
| Operating Income | $36.4 million | $23.1 million |
| Net Income | $20.1 million | $14.7 million |
| Diluted EPS | $0.17 | $0.12 |
| Gross Margin | 41.0% | 39.4% |
| Cash from Operations | $18.4 million | $17.4 million |
| Long-Term Debt | $566.1 million | $516.1 million |
| Cash and Equivalents | $185.3 million | $119.6 million |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 20% year-over-year, driven by a 19% increase in the Life and Analytical Sciences segment and a 22% increase in Optoelectronics. Growth was attributed to acquisitions (approx. 4% impact) and favorable foreign exchange rates (approx. 6% impact).
- Profitability: Operating income rose 57% to $36.4 million. Gross margin improved by 160 basis points to 41.0%, aided by productivity improvements and higher-margin products, partially offset by inflation and freight costs.
- Discontinued Operations: The company recorded a net loss of $2.9 million from discontinued operations, primarily related to the ViaCyte and Cellular Therapy Technology businesses acquired with ViaCell, which are being divested.
- Acquisitions: Significant cash outflows for acquisitions totaled $76.2 million in the quarter, including the purchase of Pediatrix Screening (PKI Genetics) for $66.3 million.
- Debt Structure: The company increased its senior unsecured revolving credit facility to $650 million and repaid a $300 million interim credit facility used for the ViaCell acquisition.
Guidance, Outlook, and Risks
- Outlook: Management anticipates that operations will generate sufficient cash to fund operating expenses, capital expenditures, and dividends in the near term. A private placement debt issuance is scheduled to close on May 30, 2008, to refinance existing borrowings.
- Restructuring: The company is executing restructuring plans (Q4 2007 Plan and ViaCell integration) with remaining liabilities of approximately $7.4 million expected to be paid through 2022.
- Legal Contingencies:
- PharmaStem: The Supreme Court denied certiorari in March 2008, finalizing a Federal Circuit ruling in PerkinElmer's favor regarding patent infringement claims (PharmaStem I). A second related case (PharmaStem II) remains stayed pending PTO re-examination.
- Enzo Biochem: Ongoing litigation regarding patent infringement and breach of contract; summary judgment motions are pending.
- Environmental: Accrued $4.3 million for environmental remediation costs.
- Market Risks: Exposure to foreign currency fluctuations (63% of business outside the U.S.) and interest rate volatility on variable-rate debt. The company uses forward contracts and interest rate hedges to mitigate these risks.
Investor Verification Checklist
- Verify the final purchase price allocation for the PKI Genetics and ViaCell acquisitions, as current figures are preliminary.
- Monitor the status of the pending private placement debt issuance scheduled for May 30, 2008.
- Track the resolution of the Enzo Biochem litigation and the PTO re-examination in the PharmaStem II case.
- Assess the impact of the $18.7 million net derivative loss on interest rate hedges currently held in other comprehensive income.
- Review the timeline for the divestiture of the ViaCyte and Cellular Therapy Technology businesses classified as discontinued operations.